gemcitabine has been researched along with pyrophosphate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bapiro, TE; Bramhall, JL; Cook, N; Courtin, A; Frese, KK; Griffiths, JR; Jodrell, DI; Madhu, B; Neesse, A; Richards, FM; Tuveson, DA | 1 |
| Jusko, WJ; Kandel, ES; Lin, Q; Qian, Z; Qu, J; Rasam, SS; Serratore, A; Shen, S; Straubinger, RM | 1 |
2 other study(ies) available for gemcitabine and pyrophosphate
| Article | Year |
|---|---|
Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Choline; Deoxycytidine; Diphosphates; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Tumor Cells, Cultured | 2014 |
Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer.
Topics: Adenocarcinoma; Cell Line, Tumor; Diphosphates; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Proteomics; Ribonucleosides; S100 Calcium-Binding Protein A4 | 2022 |